期刊
AMERICAN JOURNAL OF PATHOLOGY
卷 170, 期 1, 页码 281-292出版社
ELSEVIER SCIENCE INC
DOI: 10.2353/ajpath.2007.060485
关键词
-
类别
资金
- NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS048478] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE ON DRUG ABUSE [R01DA019674] Funding Source: NIH RePORTER
- NIDA NIH HHS [R01 DA019674, DA019674] Funding Source: Medline
- NINDS NIH HHS [R01 NS048478, NS048478] Funding Source: Medline
The novel immunomodulator FTY720 is an effective immunosuppressive agent in experimental models of transplantation and autoimmunity and is currently undergoing phase ill clinical trials for multiple sclerosis. Phosphorylated FTY720 is a structural analogue of sphingosine I-phosphate (SIP) and therefore acts as a high-affinity agonist at four of the five G protein-coupled SIP receptors. it has been well established that there exists a crosstalk between SIP and transforming growth factor (TGF)-beta signaling. Because TGF-beta is the most prominent inductor of fibrosis and myofibroblasts are primarily responsible for excessive matrix protein formation, we examined whether FTY720, in analogy to TGF-beta, induces differentiation of fibroblasts into myofibroblasts. indeed, FTY720 provoked myofibroblast differentiation comparable with that of TGF-beta. For biological efficacy, FTY720 required endogenous phosphorylation because inhibition of sphingosine kinase completely prevented FTY720 from inducing the differentiation process. Moreover, we identified the lysophospholipid receptor S1P(3) as the crucial receptor subtype for FTY720-induced myofibroblast differentiation because the effect was abolished in fibroblasts isolated from S1P(3) knockout mice. Finally, we determined that downstream of S1P(3) signaling Smad3 activation is essential for myofibroblast differentiation in response to FTY720. Thus, FTY720 may have adverse fibrotic effects related to its activity on S1P(3) signaling.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据